Provided by Tiger Trade Technology Pte. Ltd.

LAEKNA-B

8.265
+1.85528.94%
Volume:7.60M
Turnover:58.19M
Market Cap:3.74B
PE:-14.01
High:8.265
Open:6.805
Low:6.805
Close:6.410
52wk High:19.360
52wk Low:5.370
Shares:452.00M
HK Float Shares:452.00M
Volume Ratio:7.04
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.590
ROE:-10.69%
ROA:-7.60%
PB:2.67
PE(LYR):-14.01
PS:12.45

Loading ...

LAEKNA-B Shares Surge Over 5% in Morning Session as LAE002 Phase III Trial Hits Primary Endpoint, NDA Submission Imminent

Stock News
·
May 14

MSCI's May Global Small-Cap Index Rebalancing: 14 Additions Including Meitu and 21 Deletions Such as CIG

Stock News
·
May 13

Stock Track | LAEKNA-B Plummets 8.59% Intraday Amid Insider Selling Concerns

Stock Track
·
May 12

Laekna Sees Insider Stock Selling

Simply Wall St.
·
May 12

LAEKNA-B Shares Surge Over 10% in Afternoon Trading as Qilu Pharmaceutical Advances LAE002 NDA; Company Poised for Upfront and Milestone Payments

Stock News
·
May 11

Laekna Grants Restricted Share Units to Directors, Employees

MT Newswires Live
·
May 11

LAEKNA-B Issues 2.865 Million Shares to Fulfill RSU Vesting Under 2024 Share Incentive Plan

Stock News
·
May 11

Laekna-B Issues 2.87 Million New Shares for 2024 RSU Vesting, Lifting Share Base to 449.33 Million

Bulletin Express
·
May 11

Laekna files HKEX next-day return, issues 2.87 million shares at HKD 0

Reuters
·
May 11

Laekna Grants 15.32 Million RSUs; Director Awards Require Shareholder Nod

Bulletin Express
·
May 08

LAEKNA-B (02105) Grants 15.3235 Million Restricted Share Units in Total

Stock News
·
May 08

LAEKNA-B Shares Surge Over 5% in Late Trading as Qilu Pharma Advances Domestic Application for LAE002

Stock News
·
May 07

Laekna-B Keeps Share Base Unchanged in April 2026; Public Float Remains Above 25%

Bulletin Express
·
May 06

Revised Title

Stock News
·
Apr 20

Laekna Says Cancer Drug Meets Progression-free Survival Goal in Phase 3 Trial

MT Newswires Live
·
Apr 15

LAEKNA-B's Afuresertib Meets Primary Endpoint in Phase III Breast Cancer Trial

Stock News
·
Apr 15

Laekna says phase III afuresertib breast cancer trial meets PFS endpoint

Reuters
·
Apr 15

莱凯医药2025年实现首笔收入并稳步推进ActRII管线,研发投入上升净亏损收窄

Bulletin Express
·
Apr 13

Laekna publishes 2025 annual report

Reuters
·
Apr 13

Weight-Loss Drug Market Competition Intensifies as Laekna's LAE102 Shows Superior Clinical Data Over Small RNA Therapies

Deep News
·
Apr 09